国务院常务会议解读丨规范生物医学新技术应用 助力健康中国建设

Core Points - The State Council's executive meeting approved the draft regulation for the management of clinical research and clinical application of biomedical new technologies, aiming to promote innovation and accelerate the transformation of research results in the biomedical industry [1] - The meeting emphasized the importance of balancing development and safety, ensuring the quality and safety of clinical applications while effectively preventing various risks [1] - The regulation aims to facilitate medical progress, ensure healthcare quality and safety, and protect human dignity and health by clarifying responsibilities among research institutions, enterprises, and medical institutions [1] Summary by Categories Regulation and Management - The draft regulation is designed to standardize the clinical research and application of new biomedical technologies, which is crucial for medical advancement and patient safety [1] - It aims to break down barriers between research and application, accelerating the benefits of cutting-edge biomedical technologies to the public [1] Industry Impact - The regulation is expected to enhance the quality and safety of medical services, thereby fostering the development of the biomedical industry [1] - By establishing clear responsibilities and enhancing risk warning and emergency management, the regulation marks a significant step towards modernizing governance in this field [1]